Biological E. expands vaccine facility in Hyderabad with $50M DFC financing

Biological E. Limited finalized a $50 million financing arrangement with the U.S. International Development Finance Corporation to expand its COVID-19 vaccine manufacturing facility in Hyderabad, India. The expansion aims to support production of more than one billion vaccine doses by end of 2022.

“DFC's partnership with Biological E will support capacity for production of more than one billion vaccine doses by the end of 2022 for India and for developing countries around the world.”dfc.gov

• 1 source
• dfc.govDFC and Biological E. Limited Finalize Financing ...Oct 25, 2021

Summarized from public sources; check the original articles before acting on it.